Comprehensive Monograph on Follitropin (rhFSH)

Section 1: Executive Summary

Follitropin is a recombinant form of human Follicle-Stimulating Hormone (FSH), a cornerstone gonadotropin in the therapeutic management of infertility in both men and women.[1] As a biotechnologically derived therapeutic, it represents a significant advancement over earlier gonadotropins extracted from human urine, offering superior purity, batch-to-batch consistency, and a more favorable safety profile by eliminating the risk of urinary protein contaminants.[2] The primary function of follitropin is to act as an agonist of the FSH receptor, thereby stimulating ovarian follicular development in females and spermatogenesis in males.[1] Its principal clinical applications are in ovulation induction for anovulatory women, controlled ovarian stimulation for Assisted Reproductive Technologies (ART) such as in vitro fertilization (IVF), and the treatment of male hypogonadotropic hypogonadism.[5]

The continued development of follitropin has yielded distinct molecular variants—alfa, beta, and delta—which are produced in different recombinant cell lines. This variation in manufacturing results in unique glycosylation patterns that directly influence their pharmacokinetic profiles and, consequently, their clinical dosing strategies.[1] This evolution has culminated in the development of sophisticated, personalized dosing algorithms for the newest variant, follitropin delta, which are based on patient-specific biomarkers like Anti-Müllerian Hormone (AMH) and body weight to optimize the balance between efficacy and safety.[10]

While follitropin therapy is highly effective, its use is associated with significant risks that require careful patient selection and monitoring. The most notable of these is Ovarian Hyperstimulation Syndrome (OHSS), a potentially life-threatening condition. Other serious risks include thromboembolic events and the increased likelihood of multi-fetal gestation.[1] The pharmaceutical market for follitropin is mature and competitive, comprising well-established originator products such as Gonal-f (follitropin alfa) and Follistim (follitropin beta), alongside a growing number of biosimilar products, including Bemfola and Ovaleap, which have demonstrated comparable efficacy and safety in rigorous clinical trials.[13] This report provides an exhaustive analysis of follitropin, covering its molecular biology, pharmacology, clinical applications, safety profile, and the regulatory and commercial landscape.

Section 2: Molecular Profile and Manufacturing of Recombinant FSH

2.1. Structure and Physicochemical Characteristics

Follitropin is a complex glycoprotein hormone with a molecular weight of approximately 35.5 kDa.[4] Its structure is that of a heterodimer, composed of two distinct polypeptide subunits, designated alpha (

α) and beta (β), which are linked by non-covalent bonds.[1]

The α-subunit, containing 92 amino acids, is a common structural component shared with other human glycoprotein hormones, including Luteinizing Hormone (LH), Thyroid-Stimulating Hormone (TSH), and human Chorionic Gonadotropin (hCG).[1] In contrast, the

β-subunit is unique to FSH. It consists of 111 amino acids and is responsible for conferring the hormone's biological specificity and its high-affinity interaction with the FSH receptor.[1] The biological activity of follitropin is dependent on the proper association of both the

α and β subunits into the heterodimeric form.[4]

A critical feature of follitropin's structure is its extensive glycosylation, a post-translational modification essential for its folding, stability, and biological function. The protein possesses four N-linked glycosylation sites: two on the α-subunit at asparagine (Asn) residues 51 and 78, and two on the β-subunit at Asn residues 7 and 24.[1] These oligosaccharide side chains are complex structures composed of various sugars, including N-acetylgalactosamine, mannose, N-acetylglucosamine, galactose, and terminal sialic acid residues.[4]

The chemical identification of follitropin is associated with the Chemical Abstracts Service (CAS) Number 146479-72-3.[17] Some chemical databases report a molecular formula of

C42H65N11O12S2 and a corresponding molecular weight of approximately 980.16 g/mol.[17] However, this formula represents a small peptide fragment and does not reflect the complete, complex structure of the full glycosylated heterodimer. More accurate mass estimations for the entire protein are significantly higher, with values reported around 10,206 Da for follitropin alfa and an average of 22,700 Da for the broader follitropin entity, reflecting the substantial contribution of the carbohydrate moieties and the inherent heterogeneity of glycoproteins.[22]

2.2. Recombinant Production and Variants

Modern follitropin preparations are products of recombinant DNA technology, a manufacturing process that ensures high purity, consistent specific activity, and eliminates the risk of contamination from urinary proteins, which was a concern with earlier gonadotropin preparations.[2] The specific cell line used for production gives rise to different variants of follitropin, primarily distinguished by their glycosylation patterns.

Follitropin Alfa and Follitropin Beta (CHO Cell Lines)

Follitropin alfa (the active ingredient in Gonal-f, Bemfola, and Ovaleap) and follitropin beta (the active ingredient in Follistim and Puregon) are both produced in genetically modified Chinese Hamster Ovary (CHO) cell lines.1 These cells are transfected with plasmids containing the DNA sequences that encode for the human FSH

α- and β-subunits. The resulting recombinant proteins have amino acid sequences identical to that of endogenous human FSH. However, the post-translational glycosylation process in CHO cells results in oligosaccharide side chains that are very similar, but not completely identical, to those of the native human hormone.[1] This leads to slight variations in the profile of glycoforms. Specifically, follitropin alfa is reported to have a glycoform profile that resembles the FSH isoform found at mid-cycle, whereas follitropin beta's profile is more akin to the isoform present in the early follicular phase.[3] Despite these subtle molecular differences, extensive physicochemical testing and bioassays have demonstrated that follitropin alfa and follitropin beta are largely indistinguishable in terms of their biological activity and clinical effects.[1]

Follitropin Delta (Human Cell Line)

Follitropin delta (the active ingredient in Rekovelle) represents a more recent development in recombinant FSH production. It is manufactured using a human cell line (PER.C6), a fully characterized cell line derived from human retinal cells.8 The use of a human cell line results in a glycosylation pattern that more closely mimics that of native human FSH. A key distinction is the presence of both ${\alpha}$2,3- and ${\alpha}$2,6-linked sialic acid residues on follitropin delta's glycans, whereas CHO-derived follitropins predominantly feature only ${\alpha}$2,3-linked sialic acid.9 This difference in sialylation has significant implications for the molecule's pharmacokinetic properties.

Purification Process

Following expression in bioreactors, the secreted follitropin is harvested from the cell culture supernatant and subjected to a rigorous, multi-step purification process to isolate the active heterodimer and ensure product purity and consistency. This process typically involves a series of chromatographic techniques, which may include anion-exchange, hydrophobic interaction, dye affinity, and immunoaffinity chromatography.31 These steps effectively remove process-related impurities, such as host cell proteins, DNA, and media components, as well as product-related impurities like free subunits, aggregates, or improperly folded proteins. The result is a highly purified preparation with a consistent isoform profile and high specific activity, suitable for therapeutic use.3

The choice of manufacturing platform is not merely a technical detail but a fundamental determinant of the final product's molecular and pharmacological characteristics. The progression from CHO cells to human cell lines for follitropin production exemplifies how biopharmaceutical engineering can directly influence clinical application. The host cell line's machinery for post-translational modifications, particularly glycosylation, dictates the final structure of the glycoprotein. Human cell lines, such as PER.C6, are capable of generating glycosylation patterns, including specific sialic acid linkages (${\alpha}$2,3 and ${\alpha}$2,6), that are more homologous to native human proteins compared to those from non-human cells like CHO, which primarily produce ${\alpha}$2,3 linkages.[9] This seemingly subtle molecular difference has profound consequences. The degree and type of sialylation are critical factors governing a glycoprotein's circulating half-life and its mechanism of clearance from the body. More highly sialylated forms are generally cleared more slowly.[34] This molecular distinction is the direct cause of the observed pharmacokinetic differences between follitropin delta and the earlier alfa and beta variants. Follitropin delta exhibits lower clearance and consequently higher systemic exposure, a behavior linked to its interaction with the asialoglycoprotein receptor (ASGPR) in the liver—a clearance pathway that is less significant for follitropin alfa.[9] This fundamental pharmacokinetic difference necessitates a completely different approach to clinical dosing. Follitropin alfa and beta are dosed based on their biological activity, measured in International Units (IU). In contrast, the higher potency and longer half-life of follitropin delta require it to be dosed by mass (micrograms, mcg) using a predictive algorithm to prevent overexposure and mitigate the risk of OHSS.[10] Thus, the evolution in manufacturing technology has enabled a paradigm shift in fertility treatment, moving from empirical, reactive dose adjustments to a proactive, personalized medicine approach based on patient-specific biomarkers.

Section 3: Comprehensive Pharmacological Profile

3.1. Mechanism of Action at the Cellular and Molecular Level

Follitropin, as a recombinant form of endogenous FSH, exerts its physiological effects by acting as a selective agonist at the Follicle-Stimulating Hormone Receptor (FSHR).[1] The FSHR is a member of the G-protein coupled receptor (GPCR) superfamily and is primarily expressed on the surface of ovarian granulosa cells in females and testicular Sertoli cells in males.[1]

The binding of follitropin to the extracellular domain of the FSHR induces a conformational change in the receptor. This change facilitates the coupling and activation of an intracellular heterotrimeric G-protein, specifically the stimulatory G-protein (Gαs).[29] Activation of

Gαs leads to the stimulation of the enzyme adenylyl cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP concentration serves as a critical second messenger in the FSH signaling cascade.[29]

Elevated levels of cAMP lead to the activation of Protein Kinase A (PKA), which functions as a master regulator by phosphorylating a multitude of downstream protein targets and transcription factors. This PKA-mediated phosphorylation initiates a complex and intertwined network of intracellular signaling pathways that ultimately govern the cellular response to FSH. Key downstream pathways activated include:

The Phosphatidylinositol-3-kinase (PI3K)/Akt pathway: This pathway is crucial for promoting cell survival, maturation, and proliferation, and it plays a significant anti-apoptotic role.[1]
The Mitogen-Activated Protein Kinase (MAPK)/Extracellular signal-regulated kinase (ERK) pathway: This cascade is heavily involved in regulating cell proliferation, differentiation, and steroidogenesis.[37]

The coordinated activation of these pathways leads to the modulation of gene expression, upregulating the transcription of genes essential for gametogenesis. In granulosa cells, this includes genes for enzymes involved in steroid hormone synthesis (e.g., aromatase, which converts androgens to estrogens), growth factors, and the LH receptor.[29] In Sertoli cells, it involves the production of proteins necessary for spermatogenesis.

FSH signaling exhibits a sophisticated dual function in regulating apoptosis. On one hand, FSH is a primary survival factor for small antral follicles (2–5 mm in diameter), rescuing them from programmed cell death (apoptosis) and allowing a cohort of follicles to begin development each cycle.[4] This anti-apoptotic effect is largely mediated by the PI3K/Akt and ERK1/2 survival pathways. On the other hand, the FSH signaling network also incorporates pro-apoptotic elements, such as the p38 MAPK pathway. This dual potential is critical for the physiological process of selecting a single dominant follicle for ovulation while the remaining follicles in the cohort undergo atresia. The precise balance between these pro-survival and pro-apoptotic signals, likely influenced by the local hormonal milieu and receptor density, determines the ultimate fate of each follicle.[37]

3.2. Pharmacodynamics

The pharmacodynamic effects of follitropin are the direct physiological consequences of its mechanism of action on the gonads.

In Females: Follitropin is the principal hormone driving follicular recruitment and development in the ovaries.[1] In women who do not have primary ovarian failure, the administration of exogenous follitropin stimulates the growth and maturation of ovarian follicles.[1] This follicular growth is accompanied by a measurable increase in the production and secretion of gonadal steroids, particularly estradiol, and the peptide hormone inhibin B. These hormones serve as key pharmacodynamic markers for monitoring the ovarian response to stimulation.[25] In natural cycles, this process leads to the development of a single dominant follicle. In the context of ART, supraphysiological doses of follitropin are used for controlled ovarian stimulation to induce the development of multiple follicles simultaneously, thereby increasing the number of oocytes available for retrieval for procedures like IVF or gamete intrafallopian transfer (GIFT).[1]

In Males: In men with hypogonadotropic hypogonadism, a condition characterized by deficient pituitary gonadotropin secretion, follitropin therapy is essential for initiating and maintaining spermatogenesis.[1] It acts directly on the Sertoli cells within the seminiferous tubules of the testes. This stimulation induces the Sertoli cells to secrete androgen-binding protein (ABP), which binds testosterone and maintains the high intratesticular testosterone concentrations necessary for the maturation of spermatogonia into mature spermatozoa.[4] Follitropin therapy for spermatogenesis is almost always preceded and accompanied by treatment with hCG, which mimics the action of LH to stimulate testosterone production by the Leydig cells, thereby ensuring an adequate androgenic environment for the FSH to act upon.[7]

3.3. Pharmacokinetics

The pharmacokinetic profile of follitropin describes its absorption, distribution, metabolism, and excretion. This profile can vary between the different recombinant variants due to the molecular differences outlined previously.

Absorption and Bioavailability: Following subcutaneous injection, the most common route of administration, the absorption of follitropin into the systemic circulation is relatively slow. The rate of absorption is found to be slower than the rate of elimination, making the overall pharmacokinetics of the drug absorption rate-limited.[1] For follitropin alfa, the absolute bioavailability is estimated to be between 66% and 76%.[1]

Distribution: After absorption, follitropin is distributed throughout the body. The volume of distribution is relatively small, with a reported value of approximately 8 L for follitropin beta in healthy, pituitary-suppressed women, indicating that the drug is primarily confined to the extracellular fluid compartment.[38]

Elimination and Half-Life: The elimination of follitropin from the body is a key area where the different variants diverge. Follitropin delta, produced in a human cell line, exhibits a longer mean elimination half-life, reported to be in the range of 50.5 to 60.9 hours after a single dose.[34] This is significantly longer than the half-life of follitropin alfa (approximately 37 hours) and follitropin beta (ranging from approximately 27 to 44 hours depending on the study).[3] This difference is attributed to the more extensive sialylation of follitropin delta, which reduces its rate of clearance by the liver.[34]

Influence of Patient Factors: Patient-specific characteristics can significantly influence the pharmacokinetics of follitropin. Body weight has been identified as a major determinant of serum FSH concentrations. Studies have shown an inverse relationship, where higher body weight is associated with a lower systemic drug exposure (as measured by the Area Under the Curve, AUC).[38] This observation provides a strong pharmacokinetic rationale for considering body weight in dosing decisions to ensure adequate drug levels are achieved, a principle that is formally integrated into the dosing algorithm for follitropin delta.[10]

The distinct pharmacokinetic properties of follitropin delta, particularly its lower clearance and longer half-life compared to the CHO-derived alfa and beta variants, are not merely scientific observations but are the foundational basis for its unique clinical application.[34] A longer half-life implies that the drug will accumulate to a greater extent with repeated daily dosing, which heightens the risk of ovarian overstimulation if dosing is not carefully controlled. Simultaneously, the clear inverse relationship between a patient's body weight and their systemic drug exposure means that a standard, fixed dose is likely to result in under-dosing in heavier individuals and over-dosing in lighter individuals.[38] These two pharmacokinetic principles converge to provide the compelling rationale for the development of the Rekovelle (follitropin delta) dosing algorithm. This algorithm prospectively incorporates both body weight (to normalize for drug distribution and exposure) and serum AMH levels (as a pharmacodynamic marker to predict ovarian sensitivity).[10] This represents a significant departure from the more empirical "start low and titrate" approach common with older follitropins. It is a direct clinical application of pharmacokinetic and pharmacodynamic science, aiming to standardize the ovarian response by personalizing the dose from the very beginning of the treatment cycle. This innovative strategy is designed to improve the predictability of treatment, optimize the yield of oocytes, and, most critically, enhance safety by reducing the incidence of OHSS.

Section 4: Clinical Efficacy and Therapeutic Applications

4.1. Approved Indications in Female Infertility

Follitropin is a cornerstone therapy for several forms of female infertility, with well-established indications supported by extensive clinical evidence. Its use is contingent on a thorough gynecologic and endocrinologic evaluation to confirm the diagnosis and rule out contraindications.

Ovulation Induction (OI): Follitropin is indicated for the induction of ovulation and subsequent pregnancy in women with oligo-ovulation or anovulation, where the cause of infertility is functional and not due to primary ovarian failure. This indication is particularly relevant for women who have failed to respond to treatment with clomiphene citrate, a first-line oral ovulation induction agent.[5]
Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART): A primary application of follitropin is for the stimulation and development of multiple follicles in ovulatory women participating in an ART program. This includes procedures such as In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI). The goal is to increase the number of mature oocytes available for retrieval, fertilization, and subsequent embryo transfer, thereby improving the chances of a successful pregnancy.[1]
Severe Luteinizing Hormone (LH) and FSH Deficiency: In the specific population of women with severe deficiency of both LH and FSH (hypogonadotropic hypogonadism), follitropin is used in combination with a lutropin alfa (recombinant LH) preparation. This dual hormone replacement is necessary to stimulate follicular development and maturation effectively.[13]

4.2. Approved Indications in Male Infertility

Follitropin also plays a crucial role in the treatment of specific forms of male infertility, requiring a complete medical and endocrinologic evaluation prior to initiation of therapy.

Induction of Spermatogenesis: Follitropin is indicated for the induction of spermatogenesis in men diagnosed with primary or secondary hypogonadotropic hypogonadism, a condition where inadequate pituitary gonadotropin secretion leads to impaired sperm production. This indication is for men in whom the cause of infertility is not primary testicular failure (i.e., the testes are capable of responding to hormonal stimulation).[1] Treatment is administered concomitantly with human chorionic gonadotropin (hCG) therapy, which is used to normalize serum testosterone levels prior to and during follitropin administration.[7]

4.3. Summary of Key Clinical Trials

The clinical development and approval of follitropin and its variants are supported by a robust body of evidence from numerous clinical trials across all phases of development.

Phase 1-2 Studies: Initial trials in healthy volunteers were designed to establish the pharmacokinetic and safety profiles of the different follitropin preparations and to determine appropriate dose ranges for further study.[52]

Phase 3 Pivotal Trials: Large-scale, randomized controlled trials were conducted to establish efficacy and safety for specific indications.

Originator Products: The efficacy of the originator products, Gonal-f (follitropin alfa) and Follistim (follitropin beta), was established in pivotal trials that compared them to the then-standard-of-care, urinary-derived gonadotropins. These studies demonstrated that the recombinant products had comparable or superior efficacy in both ovulation induction and ART cycles, with the added benefits of higher purity and consistency.[25]
Biosimilar Approval Trials: The regulatory pathway for biosimilar follitropins, such as Bemfola and Ovaleap, required head-to-head comparison with the reference product, Gonal-f. The primary endpoint in these trials was typically the number of oocytes retrieved following controlled ovarian stimulation in an ART setting. These studies, including the trial for Bemfola (NCT01121666), successfully demonstrated non-inferiority or therapeutic equivalence to the reference product, providing the basis for their approval and the extrapolation of efficacy to all of the reference product's indications.[13]
Follitropin Delta (Rekovelle): The clinical development of follitropin delta was anchored by the ESTHER-1 trial, a large Phase 3 study that employed an innovative design. It compared the individualized, biomarker-driven dosing algorithm of follitropin delta against a conventional, non-biomarker-based dosing strategy with follitropin alfa. The trial successfully demonstrated non-inferiority for the co-primary endpoints of ongoing pregnancy and implantation rates. Importantly, it also showed that the individualized follitropin delta regimen resulted in a higher proportion of patients achieving an optimal oocyte yield (8–14 oocytes) and a significantly lower incidence of OHSS and/or the need for OHSS preventive measures, thereby showcasing an improved balance of efficacy and safety.[42]

Phase 4 Post-Marketing and Real-World Studies: Following approval, Phase 4 studies and observational trials continue to be conducted to gather further data on the long-term safety and effectiveness of follitropin products in routine clinical practice. These studies explore outcomes in diverse patient populations, compare different treatment protocols, and provide valuable real-world evidence. For example, the recruiting study NCT06921395 aims to compare two different follitropin products in IVF-ET cycles [62], while the prospective study NCT05173597 is designed to evaluate the performance of the follitropin delta individualized dosing regimen under real-world conditions.[61]

A structured summary of these trials is essential for understanding the evidence base that underpins the clinical use of various follitropin products. The following table provides an at-a-glance overview of key studies, allowing for a rapid comparison of trial designs and outcomes. This is particularly useful for discerning the different regulatory and clinical development strategies. For biosimilars, the focus on demonstrating equivalence in a surrogate endpoint (number of oocytes) is a common and accepted approach that allows for regulatory extrapolation to other indications. In contrast, the trial design for follitropin delta highlights a shift towards demonstrating not just equivalence, but the added value of an innovative, personalized dosing strategy aimed at optimizing the safety-efficacy balance.

Trial Identifier	Follitropin Product(s) Studied	Phase & Status	Indication/Purpose	Primary Endpoint(s)	Key Finding/Outcome
NCT01121666	Bemfola® (follitropin alfa) vs. Gonal-f® (follitropin alfa)	Phase 3, Completed	Controlled Ovarian Stimulation for ART	Number of oocytes retrieved	Demonstrated therapeutic equivalence to the reference product.55
ESTHER-1	Rekovelle® (follitropin delta) vs. Gonal-f® (follitropin alfa)	Phase 3, Completed	Controlled Ovarian Stimulation for ART	Ongoing pregnancy rate; Ongoing implantation rate	Demonstrated non-inferiority for pregnancy outcomes with a lower incidence of OHSS.42
NCT02349945	Follitropin	Phase 2/3, Completed	Male Infertility	Efficacy of FSH therapy based on FSH receptor polymorphism	Investigated genetic factors influencing treatment response in men.63
NCT03177538	Corifollitropin alfa vs. Follitropin + Lutropin alfa	Phase 4, Completed	Female Infertility in suboptimal responders	Number of oocytes retrieved	Compared a long-acting FSH with a daily FSH/LH combination.64
NCT05173597	Rekovelle® (follitropin delta)	Not Applicable (NIS), Recruiting	Infertility / ART	Real-world effectiveness and safety	To explore performance of individualized dosing regimen in routine clinical practice.61
NCT06921395	Fang Le Shu (follitropin) vs. Guo Na Fen (follitropin)	Phase 4, Recruiting	Female Infertility / IVF-ET	Clinical pregnancy rate	To evaluate efficacy and safety of two follitropin products.62

Section 5: Safety, Tolerability, and Risk Management

5.1. Profile of Adverse Events

The safety profile of follitropin has been well-characterized through extensive clinical trials and post-marketing surveillance. Adverse events can be categorized by frequency and are generally similar across the different follitropin alfa and beta products.

Common Adverse Reactions (${\geq}$5%):

In Women: The most frequently reported adverse reactions include headache, ovarian cysts, abdominal and/or pelvic pain, nausea, and injection site reactions (such as pain, erythema, bruising, and swelling). Ovarian Hyperstimulation Syndrome (OHSS) is also a common and significant risk.[1]
In Men: The most common adverse events are dermatological, including acne and seborrhea. Other frequent reactions include injection site pain, fatigue, and gynecomastia (enlargement of breast tissue).[44]

Less Common Adverse Reactions:

Other reported side effects include mood changes, dizziness, breast tenderness, flatulence, and intermenstrual bleeding in women.50

Post-marketing Reports:

Spontaneous post-marketing reports have identified hypersensitivity reactions as a potential risk. These can range from mild skin reactions to more severe systemic reactions, including anaphylaxis and exacerbation of asthma.1

5.2. Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is the most serious and clinically significant complication associated with the use of gonadotropins for controlled ovarian stimulation. It is a systemic condition resulting from an excessive ovarian response to stimulation.

Pathophysiology and Risk: The underlying mechanism of OHSS involves a dramatic increase in vascular permeability, driven by the release of vasoactive substances (such as vascular endothelial growth factor, VEGF) from hyperstimulated ovaries. This leads to a massive shift of fluid from the intravascular space into the third space, resulting in complications such as ascites, pleural effusion, and an increased risk of thromboembolic events due to hemoconcentration.[29]

Clinical Presentation: The clinical spectrum of OHSS ranges from mild to severe.

Mild OHSS: Characterized by abdominal bloating, mild abdominal pain, and nausea.
Severe OHSS: Presents with rapid weight gain, severe abdominal pain and distension, persistent nausea and vomiting, decreased urine output (oliguria), and difficulty breathing (dyspnea). Severe OHSS is a medical emergency that can be life-threatening and requires hospitalization.[12]

Prevention and Management: The primary strategy for managing OHSS is prevention. This involves careful patient selection, individualized dosing protocols, and intensive monitoring of the ovarian response using transvaginal ultrasound (to assess follicular size and number) and serum estradiol measurements. If monitoring indicates an excessive ovarian response (e.g., a very high number of developing follicles or rapidly rising estradiol levels), the most effective preventive measure is to withhold the final trigger shot of hCG. This prevents the final maturation of the follicles and the luteinization process that drives severe OHSS.[74] If OHSS develops, management is primarily supportive and symptomatic, focusing on maintaining fluid and electrolyte balance and preventing complications.[43]

5.3. Contraindications, Warnings, and Precautions

The use of follitropin is contraindicated in certain patient populations and carries several important warnings that require careful consideration by the prescribing physician.

Absolute Contraindications:

Hypersensitivity: A history of prior hypersensitivity or allergic reaction to follitropin or any of its excipients.[38]
Primary Gonadal Failure: High baseline levels of FSH are indicative of primary ovarian or testicular failure, a condition in which the gonads are unable to respond to gonadotropin stimulation, rendering follitropin therapy ineffective.[38]
Uncontrolled Endocrinopathies: The presence of uncontrolled non-gonadal endocrine disorders, such as those of the thyroid, adrenal, or pituitary glands, must be addressed before initiating therapy.[73]
Hormone-Dependent Tumors: Follitropin is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (e.g., breast, ovary, uterus, testis) or tumors of the pituitary gland or hypothalamus.[38]
Pregnancy: Follitropin is contraindicated in pregnant women.[1]
Other Gynecological Conditions: In women, contraindications include abnormal uterine bleeding of undetermined origin and the presence of ovarian cysts or enlargement not caused by polycystic ovary syndrome (PCOS).[38]

Major Warnings and Precautions:

Pulmonary and Vascular Complications: Treatment with gonadotropins is associated with an increased risk of venous and arterial thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. This risk exists both with and without concomitant OHSS and can be life-threatening. The risk is particularly elevated in patients with a personal or family history of thrombosis or other recognized risk factors.[1]
Ovarian Torsion: There have been reports of ovarian torsion (twisting of the ovary) following treatment with gonadotropins. This may be related to risk factors such as OHSS, pregnancy, previous abdominal surgery, or the presence of ovarian cysts.[43]
Multi-fetal Gestation and Birth: The use of follitropin for ovulation induction or ART significantly increases the likelihood of multiple pregnancies. Multi-fetal gestations carry higher risks of maternal and fetal complications, including preterm delivery and low birth weight. Patients should be counseled about this risk before starting treatment.[1]
Ectopic Pregnancy: Infertile women undergoing ART often have underlying tubal abnormalities, which increases their risk of an ectopic pregnancy. Early confirmation of an intrauterine pregnancy via ultrasound is crucial.[38]

5.4. Drug-Drug Interactions

While formal, prospective drug-drug interaction studies have not been conducted for most follitropin products, analysis of pharmacological databases indicates a number of potential interactions that could affect the efficacy or safety of treatment.[1] A consolidated summary of these potential interactions is crucial for clinical awareness and risk mitigation. The interactions can be broadly categorized by their potential clinical consequence, which may hint at different underlying mechanisms. For instance, drugs that decrease efficacy might interfere with hormonal signaling pathways or alter drug metabolism, while those that increase adverse effects may have additive sympathomimetic or cardiovascular properties.

Interaction Type	Interacting Drug/Class	Specific Examples	Potential Clinical Consequence
Decreased Therapeutic Efficacy of Follitropin	Tyrosine Kinase Inhibitors	Acalabrutinib, Asciminib, Bosutinib, Imatinib	Suboptimal ovarian response or spermatogenesis due to potential interference with cellular signaling pathways.
	Selective Serotonin Reuptake Inhibitors (SSRIs)	Citalopram, Escitalopram, Fluoxetine, Paroxetine, Sertraline	Potential for reduced therapeutic effect, mechanism not fully elucidated.
	Antidiabetic Agents	Chlorpropamide, Glipizide, Glyburide	Potential for decreased efficacy of follitropin.
Increased Risk/Severity of Adverse Effects	Sympathomimetic Agents	Amphetamine, Dextroamphetamine, Ephedrine, Pseudoephedrine	Additive cardiovascular effects, potentially increasing risk of hypertension or tachycardia.
	Beta-Blockers	Acebutolol, Labetalol	Complex interactions, potentially increasing risk of adverse effects.
Increased Risk of Cardiac Arrhythmia	Tricyclic Antidepressants (TCAs)	Amitriptyline, Clomipramine, Doxepin, Imipramine	Additive effects on cardiac conduction, increasing the risk of arrhythmias.

Section 6: Formulations, Dosing, and Administration

6.1. Commercial Formulations and Brand Overview

The global market for follitropin includes several well-established originator products and a growing number of biosimilars, available in various formulations and delivery systems designed to meet different clinical needs and improve patient convenience.

Originator Products:

Gonal-f® (follitropin alfa): Manufactured by EMD Serono (a business of Merck KGaA), Gonal-f is a leading brand available globally. Formulations include lyophilized powder in multi-dose vials for reconstitution (450 IU and 1050 IU strengths) and a ready-to-use liquid solution in the Gonal-f® RFF Redi-ject®, a pre-filled, disposable pen available in 300 IU, 450 IU, and 900 IU strengths.[7]
Follistim® (follitropin beta): Manufactured by Organon, Follistim is another major originator product. It is available as the Follistim® AQ Cartridge, a ready-to-use liquid formulation in cartridges (300 IU, 600 IU, and 900 IU strengths) designed for use with the reusable, multi-dose Follistim Pen®.[48]
Rekovelle® (follitropin delta): Manufactured by Ferring Pharmaceuticals, Rekovelle is a newer originator product with a distinct molecular profile. It is supplied as a solution for injection in pre-filled, multi-dose pens available in 12 mcg, 36 mcg, and 72 mcg strengths.[11]

Biosimilar Products:

Bemfola® (follitropin alfa): A biosimilar to Gonal-f, Bemfola is manufactured by Gedeon Richter (following its acquisition of Finox Biotech). It is available in a range of single-use, disposable, pre-filled pens with strengths of 75 IU, 150 IU, 225 IU, 300 IU, and 450 IU.[100]
Ovaleap® (follitropin alfa): Another biosimilar to Gonal-f, Ovaleap is marketed by Theramex (and was previously launched by Teva). It is supplied in cartridges (300 IU, 450 IU, and 900 IU strengths) for use with the reusable Ovaleap Pen®.[110]

6.2. Dosing Regimens and Individualization

Dosing of follitropin is highly individualized and depends on the specific indication, the patient's ovarian response (monitored via ultrasound and serum estradiol levels), and the specific product being used.

Ovulation Induction (Follitropin Alfa/Beta): Treatment typically begins with a low starting dose, commonly 50 IU to 75 IU administered daily. The dose is then titrated upwards in small increments (e.g., 25 IU to 37.5 IU) at weekly or bi-weekly intervals until an adequate follicular response is achieved. The maximum recommended daily dose is generally between 250 IU and 300 IU.[6]
ART (Follitropin Alfa/Beta): For controlled ovarian stimulation, starting doses are higher, typically in the range of 150 IU to 225 IU daily. Dose adjustments are made more frequently, usually every 3 to 5 days, based on the patient's response. The maximum daily dose is generally between 450 IU and 600 IU.[6]
Induction of Spermatogenesis: Following pre-treatment with hCG to normalize testosterone levels, a typical follitropin regimen is 150 IU administered three times per week, or a total of 450 IU per week divided into two or three injections.[6]
Personalized Dosing (Follitropin Delta): The dosing for Rekovelle is fundamentally different and is not based on IU. For the first treatment cycle, the daily dose is fixed from the start, calculated using a validated algorithm that incorporates two patient-specific parameters: serum AMH concentration and body weight. For women with a low ovarian reserve (AMH <15 pmol/L), the daily dose is a fixed 12 mcg. For women with higher ovarian reserve (AMH ${\geq}$15 pmol/L), the daily dose is calculated on a per-kilogram basis, ranging from 0.10 to 0.19 mcg/kg. The maximum daily dose in the first cycle is 12 mcg, which can be increased to a maximum of 24 mcg in subsequent cycles based on the response in the prior cycle.[10]

6.3. Patient Administration and Counseling

Effective and safe use of follitropin relies on proper patient education and training, as the medication is typically self-administered.

Route and Site of Administration: All follitropin formulations are administered via subcutaneous injection. The recommended injection sites are the abdomen (avoiding the navel), the upper arm, or the upper thigh. Patients are instructed to rotate injection sites daily to minimize local skin reactions.[6]
Pen Device Instructions: Patients using pen devices must receive thorough training from a healthcare professional. Key steps include: loading the cartridge (for reusable pens), attaching a new, sterile needle for every injection, priming the pen to remove any air and ensure proper function, accurately dialing the prescribed dose, performing the injection at a 90-degree angle, holding the button down for a specified time (e.g., 5 seconds) to ensure full dose delivery, and safely removing and disposing of the used needle in a sharps container.[100]
Patient Counseling: Essential counseling points for patients include the critical importance of adhering to the prescribed dosing schedule and timing. Patients should be advised on what to do if a dose is missed (they should not double the next dose but should contact their provider for instructions). Proper storage conditions, which typically involve refrigeration, must be explained. Most importantly, patients must be educated on the signs and symptoms of OHSS and instructed to seek immediate medical attention if they occur.[76]

The evolution of follitropin formulations provides a clear illustration of patient-centric drug development within the pharmaceutical industry. The market has shown a distinct progression from early formulations that required complex preparation, such as lyophilized powders in vials needing reconstitution, to the current standard of ready-to-use liquid formulations delivered via sophisticated pen injectors.[25] This transition was driven by a recognition of the significant challenges faced by patients undergoing fertility treatments. The daily self-injection regimen can be a source of stress and anxiety, and the need for reconstitution and manual dose measurement with a syringe introduced a considerable risk of dosing errors. The development of liquid formulations like Follistim AQ was the first major step in simplification, eliminating the reconstitution process.[28] The subsequent introduction of pen devices, such as the Follistim Pen and the Gonal-f Redi-ject, further transformed the patient experience by providing a more discreet, less intimidating, and more accurate method of delivery. These devices incorporate features designed to enhance safety and ease of use, such as audible clicks for dose setting, clear display windows, the ability to make fine-dose adjustments in small increments (e.g., 12.5 IU), and mechanisms to confirm full dose delivery.[51] This technological advancement is not just about convenience; it directly addresses the need for precision and reliability in a therapeutic area where outcomes are highly sensitive to dosing. In a competitive market populated by multiple originator and biosimilar products, these user-friendly delivery systems have become a key differentiator, reflecting an industry-wide trend towards designing products that reduce treatment burden and improve patient compliance and satisfaction.

Section 7: Regulatory and Developmental History

7.1. Evolution of Gonadotropin Therapy

The history of gonadotropin therapy for infertility is a story of scientific advancement, moving from crude biological extracts to highly purified, precisely engineered biopharmaceuticals.

The Early Era (Biological Extracts): The therapeutic potential of gonadotropins was recognized in the early 20th century, leading to the first treatment preparations derived from animal pituitary glands and, later, from human cadaveric pituitaries.[3] The supply of these materials was limited and carried risks. A major breakthrough came with the development of human menopausal gonadotropins (hMG), such as Pergonal, which were extracted and purified from the urine of postmenopausal women. These preparations contained a mixture of both FSH and LH activity and became a mainstay of fertility treatment for decades.[30]
The Recombinant Era: The 1990s marked a revolutionary shift with the application of recombinant DNA technology. This allowed for the large-scale production of human FSH in laboratory cell cultures, leading to the development of follitropin.[1] Recombinant FSH (rFSH) offered significant advantages over urinary-derived products, including higher purity, the absence of urinary protein contaminants (reducing the risk of allergic reactions), the elimination of LH activity (allowing for more precise control of stimulation), and greater batch-to-batch consistency. This technological leap forward greatly improved the safety, reliability, and standardization of ovarian stimulation protocols.
The Biosimilar Era: As the patents for the first-generation recombinant follitropin products began to expire, the regulatory pathways for biosimilar medicines opened the door for new market entrants. Biosimilars such as Ovaleap and Bemfola were developed. Their approval by regulatory agencies is based on a rigorous and comprehensive "comparability exercise," which involves extensive analytical, non-clinical, and clinical studies to demonstrate that they are highly similar to an approved reference product (in this case, Gonal-f) in terms of quality, safety, and efficacy. This has increased market competition and potentially improved access to treatment.[13]

7.2. Global Regulatory Approvals

Follitropin products have undergone rigorous evaluation by major regulatory bodies worldwide, leading to their approval for clinical use.

U.S. Food and Drug Administration (FDA):

Gonal-f® (follitropin alfa): The vial formulation of Gonal-f was first approved by the FDA in September 1997. The evolution of its delivery systems saw the approval of the Gonal-f RFF Pen on May 25, 2004, followed by the Gonal-f RFF Redi-ject pen on October 17, 2013. A redesigned version of the Redi-ject pen received approval on November 13, 2017, reflecting ongoing improvements in device technology.[89]
Follistim® AQ (follitropin beta): The ready-to-use aqueous formulation, Follistim AQ, was first approved by the FDA on March 24, 2004, for use with the Follistim Pen system.[91]

European Medicines Agency (EMA):

Gonal-f® (follitropin alfa): Received its marketing authorisation in the European Union in October 1995, making it one of the first recombinant gonadotropins available.[30]
Bemfola® (follitropin alfa biosimilar): Was granted a marketing authorisation as a biosimilar to Gonal-f on March 26, 2014.[13]
Ovaleap® (follitropin alfa biosimilar): Received its marketing authorisation as a biosimilar to Gonal-f on September 27, 2013.[56]
Rekovelle® (follitropin delta): Was granted a marketing authorisation as a new biological entity on December 12, 2016, based on its unique production in a human cell line and its novel, individualized dosing algorithm.[59]

Section 8: Conclusion

Follitropin, in its various recombinant forms, has fundamentally transformed the field of reproductive medicine. As a highly purified and consistent preparation of human FSH, it has become an indispensable tool for treating infertility, enabling countless individuals and couples to build families. The evolution of this therapeutic class—from urinary extracts to CHO-derived recombinant products and now to human cell line-derived variants—mirrors the broader progress in biotechnology, with each generation offering improvements in purity, consistency, and the potential for enhanced safety and efficacy.

The pharmacological profile of follitropin is well-understood, centered on its agonistic activity at the FSH receptor, which initiates the complex signaling cascades necessary for gametogenesis. The key clinical challenge in its use remains the delicate balance between achieving an effective therapeutic response and avoiding the significant risks of overstimulation, particularly OHSS. The development of follitropin delta (Rekovelle), with its distinct pharmacokinetic profile and its pioneering, biomarker-driven dosing algorithm, represents the current frontier in this effort. This move towards personalized medicine, tailoring treatment based on an individual's unique physiological markers, holds the promise of more predictable, safer, and potentially more effective treatment cycles.

The market landscape, now populated by both established originator brands and a growing number of biosimilars, continues to evolve. This competition, coupled with the ongoing innovation in drug delivery systems like pre-filled pens, is likely to improve patient access and convenience. Future research will continue to focus on refining patient selection, further personalizing treatment protocols, and exploring the long-term outcomes associated with these advanced therapies. Ultimately, follitropin stands as a testament to the power of biotechnology to address profound human health needs, offering a scientifically grounded and clinically effective solution for the complex challenge of infertility.

Works cited

Follitropin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00066
Recombinant follicle stimulating hormone | Human Reproduction - Oxford Academic, accessed July 23, 2025, https://academic.oup.com/humrep/article/14/6/1418/2919245
Recombinant follitropin alfa/lutropin alfa in fertility treatment - PMC - PubMed Central, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2819896/
Follicle-stimulating hormone - Wikipedia, accessed July 23, 2025, https://en.wikipedia.org/wiki/Follicle-stimulating_hormone
Follitropin, r-FSH injection (Gonal-F(R)) - Cleveland Clinic, accessed July 23, 2025, https://my.clevelandclinic.org/health/drugs/19494-follitropin-r-fsh-injection-gonal-fr
Follitropin beta (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/follitropin-beta-subcutaneous-route/description/drg-20063913
Follitropin alfa (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/follitropin-alfa-subcutaneous-route/description/drg-20063905
Controlled ovarian stimulation (COS) with follitropin delta results in higher cumulative live birth rates compared with follitropin alfa/beta in a large retrospectively analyzed real-world data set - PMC, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11841343/
Comparative pharmacology of a new recombinant FSH expressed ..., accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5510450/
Prescribing Information - Rekovelle SG, accessed July 23, 2025, https://rekovelle.sg/prescribing-information/
Rekovelle solution for injection in pre-filled multidose pen - NEW ZEALAND DATA SHEET, accessed July 23, 2025, https://www.medsafe.govt.nz/profs/datasheet/r/rekovelleinj.pdf
Follitropin Alfa (Gonal-f, Gonal-f RFF) - Uses, Side Effects, and More - WebMD, accessed July 23, 2025, https://www.webmd.com/drugs/2/drug-4730-5017/gonal-f-subcutaneous/follitropin-alfa-injection/details
Bemfola | European Medicines Agency (EMA), accessed July 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/bemfola
XM17 Follitropin Alfa (Ovaleap(®)): A Review in Reproductive Endocrine Disorders, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/27342604/
go.drugbank.com, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00066#:~:text=Follitropin%20is%20a%20human%20follicle,92%20and%20111%20amino%20acids.
Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility, accessed July 23, 2025, https://academic.oup.com/humupd/article-pdf/4/6/862/1998073/040862.pdf
146479-72-3 | CAS DataBase - ChemicalBook, accessed July 23, 2025, https://m.chemicalbook.com/CASEN_146479-72-3.htm
146479-72-3 | MFCD27501030 | Follicle-stimulating hormone - A2B Chem, accessed July 23, 2025, https://www.a2bchem.com/146479-72-3.html
Follicle-stimulating hormone CAS#: 146479-72-3 - ChemicalBook, accessed July 23, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB42130561_EN.htm
Follitropin EP Reference Standard CAS 146479-72-3 Sigma Aldrich, accessed July 23, 2025, https://www.sigmaaldrich.com/US/en/product/sial/y0001629
Follicle Stimulating Hormone | C42H65N11O12S2 | CID 62819 ..., accessed July 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Follicle-Stimulating-Hormone
KEGG DRUG: Follitropin alfa, accessed July 23, 2025, https://www.genome.jp/dbget-bin/www_bget?dr:D04429
FOLLITROPIN - precisionFDA, accessed July 23, 2025, https://precision.fda.gov/ginas/app/ui/substances/0576638a-2949-48ae-a4c6-5ed05d766182
Follitropin Alfa (Professional Patient Advice) - Drugs.com, accessed July 23, 2025, https://www.drugs.com/ppa/follitropin-alfa.html
Gonal-f | FDA, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20378scf015_gonal_lbl.pdf
GONAL-f, INN-follitropin alfa, accessed July 23, 2025, https://ec.europa.eu/health/documents/community-register/2009/2009060961148/anx_61148_en.pdf
annex i summary of product characteristics - Puregon, INN-follitropin beta, accessed July 23, 2025, https://ec.europa.eu/health/documents/community-register/2020/20201105149860/anx_149860_en.pdf
Follistim ® AQ Cartridge - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/21211s002lbl.pdf
What is the mechanism of Follitropin Beta? - Patsnap Synapse, accessed July 23, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-follitropin-beta
Gonadotropin preparations - Wikipedia, accessed July 23, 2025, https://en.wikipedia.org/wiki/Gonadotropin_preparations
Purification and Characterization of Recombinant Human Follicle ..., accessed July 23, 2025, https://www.jmb.or.kr/journal/download_pdf.php?spage=395&volume=15&number=2
US7939296B2 - Method for production of recombinant human FSH ..., accessed July 23, 2025, https://patents.google.com/patent/US7939296B2/en
Purification Process of a Recombinant Human Follicle Stimulating ..., accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8781808/
Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin ..., accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9834375/
go.drugbank.com, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00066#:~:text=FSH%2C%20the%20active%20component%20of,a%20G%2Dcoupled%20transmembrane%20receptor.
The Follitropin Receptor: Matching Structure and Function - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/27382014/
Molecular Mechanisms of Action of FSH - Frontiers, accessed July 23, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00305/full
Follistim AQ subcutaneous injection label - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021273s006lbl.pdf
Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women - PubMed, accessed July 23, 2025, https://pubmed.ncbi.nlm.nih.gov/36478528/
O-013 Population pharmacokinetics of follitropin delta during ovarian stimulation | Human Reproduction | Oxford Academic, accessed July 23, 2025, https://academic.oup.com/humrep/article/39/Supplement_1/deae108.013/7703416
REKOVELLE, INN-follitropin delta - EMA, accessed July 23, 2025, https://www.ema.europa.eu/en/documents/product-information/rekovelle-epar-product-information_en.pdf
Real-world Evidence on Follitropin Delta Individual Dosing - ClinicalTrials.gov, accessed July 23, 2025, https://clinicaltrials.gov/study/NCT05173597
GONAL-F RFF® (follitropin alfa) 75 IU Prescribing Information - EMD Serono, accessed July 23, 2025, https://www.emdserono.com/us-en/pi/gonal-f-rff-75-iu-pi.pdf
GONAL-F (follitropin alfa) Label - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020378s045,s067,s075lbl.pdf
GONAL-f | European Medicines Agency (EMA), accessed July 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f
The FOLLISTIM Pen - Organon Pro, accessed July 23, 2025, https://organonpro.com/en-us/product/follistim-aq-cartridge/dosing/the-follistim-pen/
Follistim®AQ (follitropin beta), Gonal-f™ (follitropin alfa), Gonal-f™ RFF (follitropin alfa), Menopur® (menotropins) - UHCprovider.com, accessed July 23, 2025, https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Med-Nec-Gonadotropins.pdf
HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - Organon, accessed July 23, 2025, https://www.organon.com/product/usa/pi_circulars/f/follistim_aq_cartridge/follistim_cartridge_pi.pdf
Australian Public Assessment Report for Follitropin alfa (rch), accessed July 23, 2025, https://www.tga.gov.au/sites/default/files/auspar-follitropin-alfa-rch-160408.pdf
Gonal-F: Uses, Side Effects, Alternatives & More - GoodRx, accessed July 23, 2025, https://www.goodrx.com/gonal-f/what-is
Gonal-f® Multi-Dose (follitropin alfa for injection) - EMD Serono, accessed July 23, 2025, https://www.emdseronofertility.com/en/home/our-medications/gonal-f-multidose.html
Follitropin Completed Phase 1 Trials for Healthy Volunteers (HV) Other | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00066/clinical_trials?conditions=DBCOND0114743&phase=1&purpose=other&status=completed
AQ (follitropin beta injection) FOR SUBCUTANEOUS OR INTRAMUSCULAR USE ONLY 5310190 7/05 DESCRIPTION Follistim - Amazon S3, accessed July 23, 2025, https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00066.pdf?1265922798
Attachment: Extract from Clinical Evaluation Report: Follitropin alfa (rch), accessed July 23, 2025, https://www.tga.gov.au/sites/default/files/auspar-follitropin-alfa-rch-160408-cer.docx
Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis - PMC - PubMed Central, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11788201/
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5427053/
Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study, accessed July 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8010350/
Ovaleap | European Medicines Agency (EMA), accessed July 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ovaleap
Rekovelle | European Medicines Agency (EMA), accessed July 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle
Ferring receives EU approval for REKOVELLE® (follitropin delta), accessed July 23, 2025, https://www.ferring.com/ferring-receives-eu-approval-for-rekovelle-follitropin-delta/
Real-world Evidence on Follitropin Delta Individual Dosing | Clinical Research Trial Listing, accessed July 23, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05173597/real-world-evidence-on-follitropin-delta-individual-dosing
Infertility, Female Recruiting Phase 4 Trials for Follitropin (DB00066) | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/indications/DBCOND0001338/clinical_trials/DB00066?phase=4&status=recruiting
Men Infertility Completed Phase 2 / 3 Trials for Follitropin (DB00066) | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/indications/DBCOND0120238/clinical_trials/DB00066?phase=2%2C3&status=completed
Follitropin Completed Phase 4 Trials for Female Infertility Treatment | DrugBank Online, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00066/clinical_trials?conditions=DBCOND0031380&phase=4&purpose=treatment&status=completed
GONAL-F® (follitropin alfa for injection) - EMD Serono, accessed July 23, 2025, https://www.emdseronofertility.com/en/patient/fertility-medications/gonal-f.html
Gonal-f Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 23, 2025, https://www.drugs.com/sfx/gonal-f-side-effects.html
Safety Information for FOLLISTIM® AQ Cartridge (follitropin beta injection), accessed July 23, 2025, https://www.follistim.com/safety-information/
www.medsafe.govt.nz, accessed July 23, 2025, https://www.medsafe.govt.nz/consumers/cmi/g/gonal-f-pen.pdf
Follistim Aq injection label - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021211s011lbl.pdf
Follitropin, r-FSH injection (Follistim(TM)) - Cleveland Clinic, accessed July 23, 2025, https://my.clevelandclinic.org/health/drugs/20166-follitropin-r-fsh-injection-follistimtm
Follitropin Alfa: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 23, 2025, https://www.rxlist.com/follitropin_alfa/generic-drug.htm
What are the side effects of Follitropin delta? - Patsnap Synapse, accessed July 23, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-follitropin-delta
Gonal-F Uses, Side Effects & Warnings - Drugs.com, accessed July 23, 2025, https://www.drugs.com/mtm/gonal-f.html
FOLLISTIM AQ- follitropin injection, solution - DailyMed, accessed July 23, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96f11b5d-cc7b-48aa-830a-a28e1962d871
www.mayoclinic.org, accessed July 23, 2025, https://www.mayoclinic.org/drugs-supplements/follitropin-alfa-subcutaneous-route/description/drg-20063905#:~:text=Call%20your%20doctor%20right%20away,distress%20syndrome%2C%20or%20asthma)..&sa=D&source=editors&ust=1753245914308580&usg=AOvVaw2d8J_hQMTchcs0-rEBryBp)
Follicle Stimulating Hormone Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 23, 2025, https://www.drugs.com/dosage/follicle-stimulating-hormone.html
Gonal-f, Gonal-f RFF (follitropin alfa) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 23, 2025, https://reference.medscape.com/drug/gonal-f-rff-follitropin-alfa-342804
Follitropin Alfa: Indications, Side Effects, Warnings - Drugs.com, accessed July 23, 2025, https://www.drugs.com/cdi/follitropin-alfa.html
This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021684s050s051lbl.pdf
FOLLISTIM® AQ Cartridge (follitropin beta injection) Official Site, accessed July 23, 2025, https://www.follistim.com/
go.drugbank.com, accessed July 23, 2025, https://go.drugbank.com/drugs/DB00066#:~:text=Duloxetine-,The%20therapeutic%20efficacy%20of%20Follitropin%20can%20be,used%20in%20combination%20with%20Duloxetine.&text=Entrectinib-,The%20therapeutic%20efficacy%20of%20Follitropin%20can%20be,used%20in%20combination%20with%20Entrectinib.&text=Ephedrine-,The%20risk%20or%20severity%20of%20adverse%20effects%20can%20be,Ephedrine%20is%20combined%20with%20Follitropin.
GONAL-f Pen® Product Monograph, accessed July 23, 2025, https://pdf.hres.ca/dpd_pm/00039076.PDF
Gonal-F: Package Insert / Prescribing Information - Drugs.com, accessed July 23, 2025, https://www.drugs.com/pro/gonal-f.html
Gonal-F RFF: Package Insert / Prescribing Information - Drugs.com, accessed July 23, 2025, https://www.drugs.com/pro/gonal-f-rff.html
Fertility LifeLines, accessed July 23, 2025, https://www.fertilitysavings.com/home.html
EMD Serono Fertility Portfolio for Healthcare Professionals, accessed July 23, 2025, https://www.emdseronofertility.com/home.html
Gonal-f® RFF Redi-ject® (follitropin alfa injection) - EMD Serono, accessed July 23, 2025, https://www.emdseronofertility.com/en/home/our-medications/gonal-f-rff-rediject.html
Fertility - EMD Serono, accessed July 23, 2025, https://www.emdserono.com/us-en/expertise/fertility.html
EMD Serono Receives FDA Approval for New GONAL-f RFF Redi-ject Pen - BioSpace, accessed July 23, 2025, https://www.biospace.com/emd-serono-receives-fda-approval-for-new-gonal-f-rff-redi-ject-pen
Patient Support Programs - EMD Serono, accessed July 23, 2025, https://www.emdserono.com/us-en/patients-and-caregivers/get-help-paying-for-your-medication.html
Follistim AQ (follitropin beta) FDA Approval History - Drugs.com, accessed July 23, 2025, https://www.drugs.com/history/follistim-aq.html
Follistim® AQ Follitropin Beta 900 IU Injection 1.08 mL - McKesson Medical-Surgical, accessed July 23, 2025, https://mms.mckesson.com/product/1244773/Organon-USA-Inc-78206013101
PATIENT INFORMATION Follistim® (Fol'-lis-tim) AQ Cartridge (follitropin beta) injection for subcutaneous use Read this Patien - Organon, accessed July 23, 2025, https://www.organon.com/product/usa/pi_circulars/f/follistim_aq_cartridge/follistim_cartridge_ppiifu.pdf
REKOVELLE, INN-follitropin delta, accessed July 23, 2025, https://ec.europa.eu/health/documents/community-register/2016/20161212136393/anx_136393_en.pdf
REKOVELLE®, accessed July 23, 2025, https://pdf.hres.ca/dpd_pm/00044406.PDF
follitropin delta (Rekovelle) - Scottish Medicines Consortium, accessed July 23, 2025, https://scottishmedicines.org.uk/medicines-advice/follitropin-delta-rekovelle-abbreviated-smc2670/
Ferring's Rekovelle receives marketing authorisation from EC - Pharmaceutical Technology, accessed July 23, 2025, https://www.pharmaceutical-technology.com/news/newsferrings-rekovelle-gets-marketing-authorisation-from-ec-5698047/
REKOVELLE, the first recombinant follicle stimulating hormone derived from a human cell line, is now available for Canadian women undergoing IVF and other assisted reproductive technologies - BioSpace, accessed July 23, 2025, https://www.biospace.com/rekovelle-and-174-the-first-recombinant-follicle-stimulating-hormone-derived-from-a-human-cell-line-is-now-available-for-canadian-women-undergoing-ivf-and-other-assisted-reproductive-technologies
Ferring receives Swiss approval for Rekovelle®, the first personalised fertility treatment using an approved dosing algorithm - Ferring Syntese, accessed July 23, 2025, https://www.syntese.dk/ferring-receives-swiss-approval-for-rekovelle-the-first-personalised-fertility-treatment-using-an-approved-dosing-algorithm/
Bemfola® - Medsafe, accessed July 23, 2025, https://www.medsafe.govt.nz/consumers/cmi/b/Bemfola.pdf
Bemfola 75 IU/0.125 mL, 150 IU/0.25 mL, 225 IU/0.375 mL, 300 IU/0.50 mL and 450 IU/0.75 mL solution for injection in pre-filled pen | PIL | medicines.ie, accessed July 23, 2025, https://www.medicines.ie/medicines/bemfola-75-iu-0-125-ml-150-iu-0-25-ml-225-iu-0-375-ml-300-iu-0-50-ml-and-450-iu-0-75-ml-solution-for-injection-in-pre-filled-pen-31405/patient-info
How to use the Bemfola pre-filled pen - Gedeon Richter, accessed July 23, 2025, https://www.gedeonrichter.se/wp-content/uploads/2022/02/bemfola_folder_180111_engelsk.pdf
Bemfola 450units/0.75ml solution for injection 1 pre-filled pen - Fertility2U, accessed July 23, 2025, https://www.fertility2u.com/bemfola-450units-0-75ml-solution-for-injection-1-pre-filled-pen.html
Bemfola 150 IU/0.25 ml solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) | 6833, accessed July 23, 2025, https://www.medicines.org.uk/emc/product/6833/smpc
Follitropin alfa biosimilar - Gedeon Richter - AdisInsight - Springer, accessed July 23, 2025, https://adisinsight.springer.com/drugs/800035631
Our Products - Gedeon Richter, accessed July 23, 2025, https://www.gedeonrichter.com/au/en/our-products
Genpharm Expands into Women's Health and Fertility with Finox Agreement, accessed July 23, 2025, https://www.genpharmservices.com/news/genpharm-expands-into-womens-health-and-fertility-with-finox-agreement/
Richter acquires all Bemfola® rights in respect of US, accessed July 23, 2025, https://bet.hu/newkibdata/127012045/RCH180710ER01E.pdf
Richter announces the acquisition of Finox Holding, accessed July 23, 2025, https://www.gedeonrichter.pl/en/komunikaty/richter-announces-the-acquisition-of-finox-holding/
OVALEAP (Theramex Australia Pty Ltd) | Therapeutic Goods Administration (TGA), accessed July 23, 2025, https://www.tga.gov.au/resources/prescription-medicines-registrations/ovaleap-theramex-australia-pty-ltd
Fertility treatments - Theramex, accessed July 23, 2025, https://www.theramex.com/products/fertility-treatments/
Owen Mumford Unveils New Self-Injection Pen for the Administration of Ovaleap® - Infertility Treatment, accessed July 23, 2025, https://www.ompharmaservices.com/wp-content/uploads/2018/01/Ovaleap-Press-Release.pdf
Teva Launches Ovaleap (follitropin alfa r-hFSH) In UK - Biosimilar Development, accessed July 23, 2025, https://www.biosimilardevelopment.com/doc/teva-launches-ovaleap-follitropin-alfa-r-hfsh-in-uk-0001
Ovaleap, INN-follitropin alfa - EMA, accessed July 23, 2025, https://www.ema.europa.eu/en/documents/product-information/ovaleap-epar-product-information_en.pdf
Ovaleap 900 IU/1.5 mL solution for injection - Summary of Product Characteristics (SmPC) - (emc) | 12918, accessed July 23, 2025, https://www.medicines.org.uk/emc/product/12918/smpc
REKOVELLE, accessed July 23, 2025, https://www.nps.org.au/assets/medicines/bbf40cd0-a025-446e-8538-a8d5008d737b-reduced.pdf
Follistim Pen Injection Demonstration (Follistim AQ Cartridge) - YouTube, accessed July 23, 2025, https://www.youtube.com/watch?v=BoIlixFFoDQ
Instructional Quick Guide for FOLLISTIM® AQ Cartridge (follitropin beta injection), accessed July 23, 2025, https://www.mdrusa.com/wp-content/uploads/Follistim_Instructions_English.pdf
How to Use FOLLISTIM® AQ Cartridge (follitropin beta injection), accessed July 23, 2025, https://www.follistim.com/how-to-use/
Using Your Follistim AQ Cartridge with the Follistim Pen - Dallas Fort - Worth Fertility Associates, accessed July 23, 2025, https://www.dallasfertility.com/assets/pdf/49-Using-Your-Follistim-AQ-Cartridge-With-The-Follistim-Pen.pdf
INSTRUCTIONS FOR USE FOLLISTIM® (Fol´-lis-tim) AQ Cartridge (follitropin beta) injection, for subcutaneous use Read this Instr - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021211s037lbl.pdf
Preparing and Administering Follistim® AQ Cartridge - Freedom MedTEACH Videos® | Freedom Fertility Pharmacy, accessed July 23, 2025, https://www.freedommedteach.com/eng/videos.html?play=follistim
Bemfola®: drug preparation and administration. Instituto Bernabeu - YouTube, accessed July 23, 2025, https://www.youtube.com/watch?v=5nzM0XAQvs8
CARE Fertility - Ovaleap Injection Teach - Diana Baranowski - YouTube, accessed July 23, 2025, https://www.youtube.com/watch?v=SlLcIeZx2t4
How to apply Ovaleap, for the stimulation of ovulation, step by step. - YouTube, accessed July 23, 2025, https://www.youtube.com/watch?v=URR4eeIas1A
How to Inject Ovaleap - First Use Injection - YouTube, accessed July 23, 2025, https://www.youtube.com/watch?v=ji4pClN0lKk
NDA 20-378/S-006 - accessdata.fda.gov, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-378S-006_review.pdf
Follistim AQ Cartridge and Pen - VFP Pharmacy Group, accessed July 23, 2025, https://www.vfppharmacygroup.com/education/medication-instructional-videos/follistim-aq
GONAL-f®: The originator r-hFSH-alpha - Merck Healthcare, accessed July 23, 2025, https://hcp.merckgroup.com/ae-en/fertility/portfolio/therapeutics/gonal-f.html
History of Gonadotropins - Frontiers, accessed July 23, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00429/epub
Follitropin – Knowledge and References - Taylor & Francis, accessed July 23, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Endocrinology/Follitropin/
Drug Approval Package: Gonal-F REF Pen (follitropin alfa injection ..., accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021684s000_GonalTOC.cfm
Follistim® AQ — Venable's BiologicsHQ, accessed July 23, 2025, https://biologicshq.com/product/follistim-aq/
Drug Approval Package: Follistim AQ (Follitropin Beta) NDA #021211, accessed July 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021211s000_FollistimTOC.cfm
FDA OKs Akzo's Follistim AQ - Pharmaceutical industry news | The Pharmaletter, accessed July 23, 2025, https://www.thepharmaletter.com/fda-oks-akzo-s-follistim-aq
Bemfola 75 IU/0.125 mL, 150 IU/0.25 mL, 225 IU/0.375 mL, 300 IU/0.50 mL and 450 IU/0.75 mL solution for injection in pre-filled pen - Medicines.ie, accessed July 23, 2025, https://www.medicines.ie/medicines/bemfola-75-iu-0-125-ml-150-iu-0-25-ml-225-iu-0-375-ml-300-iu-0-50-ml-and-450-iu-0-75-ml-solution-for-injection-in-pre-filled-pen-31405/doc-history
Human medicines European public assessment report (EPAR): Ovaleap, follitropin alfa, Date of authorisation: 27/09/2013, Revision: 13, Status, accessed July 23, 2025, https://efim.org/node/143225
Ferring receives acceptance of Marketing Authorisation filing from EMA for personalised fertility treatment with REKOVELLE® (follitropin delta), accessed July 23, 2025, https://www.ferring.com/ferring-receives-acceptance-of-marketing-authorisation/

AI-Powered Research

Premium Access

Follitropin Advanced Drug Monograph

Generic Name

Brand Names

Drug Type

CAS Number